Corbus Pharmaceuticals, Inc.
100 River Ridge Drive
Norwood
Massachusetts
02062
United States
Tel: 617-963-0100
Fax: 617-663-6085
Website: http://www.corbuspharma.com/
91 articles with Corbus Pharmaceuticals, Inc.
-
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
Funds will also be utilized to enhance Corbus’ pipeline of novel endocannabinoid system-targeting drug candidates, and the company’s workforce will be reduced by up to 54%.
-
Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis.
-
Clinical Catch-Up: September 7-11
9/14/2020
It was a busy week for clinical trial updates. Here’s a look. -
Lenabasum is an oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2).
-
Clinical Catch-Up: August 10-14
8/17/2020
It was a very busy week for clinical trial updates. Here’s a look. -
BioSpace Movers & Shakers, July 10
7/10/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
BioSpace Movers & Shakers, May 29
5/29/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Clinical Catch-Up: April 27-May 1
5/4/2020
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look. -
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
12/17/2018
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30%
-
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
8/8/2018
Lenabasum has reached Phase 3 clinical stage in two orphan autoimmune indications: systemic sclerosis and dermatomyositis, affecting up to 200,000 patients in the USA, EU and Japan
-
Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
6/21/2018
The New York Academy of Sciences symposium will highlight cutting edge research across the fields of inflammation, infection, and tissue regeneration, with focus on novel resolution mediators and mechanisms
-
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors.
-
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
6/6/2018
Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND
-
Corbus Pharma Announces Agreement With FDA on Phase IIb Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
1/30/2018
The Company and the FDA agreed that the event rate of pulmonary exacerbation is an acceptable sole primary efficacy endpoint for the clinical development program to support registration of lenabasum for the treatment of CF.
-
In less than four years, Corbus has grown from a tiny startup to a public company with 60 employees and four assets in the clinic.
-
Corbus' stock popped on the release of topline results from a midstage study involving its lead (and only) clinical drug, anabasum.
-
Corbus Pharmaceuticals Reports Positive Topline Results From Phase 2 Study In Rare Autoimmune Disease Dermatomyositis
10/19/2017
Corbus Pharmaceuticals Holdings announced positive topline results from its 16-week Phase II study of safety and efficacy of anabasum in dermatomyositis (“DM”).